Depression and appetite: predictors of malnutrition in gynecologic cancer

Nho, Ju-Hee; Kim, Sung Reul; Kwon, Young-Soon

doi:10.1007/s00520-014-2340-y

Cited by 41 publications

(40 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is consistent with studies reporting that social support is a significant factor correlated with nutritional risks . In this study, the mean score on the SNAQ was 14.5; this finding was similar to those in previous studies on chronic diseases, with 13.3 in patients with gynecologic cancer and 13.4 in patients with hemodialysis . The score was, however, lower than the 15.5 previously obtained in community‐dwelling older adults .…”

Section: Discussionsupporting

confidence: 92%

“…The SNAQ includes four questions, and scores on the SNAQ range from 4 to 20, with higher scores indicating a better appetite. The Korean version of the SNAQ has well‐established validity, and Cronbach's alpha for the scale was 0.81 in a previous study and 0.72 in this study.…”

Section: Methodssupporting

confidence: 61%

“…The nutritional status of schizophrenia patients was previously measured using anthropometric parameters such as body weight and BMI, rather than through the use of multifaceted tools such as the MNA . However, it has been reported that a single indicator such as an anthropometric or biochemical parameter does not accurately reflect nutritional status in other chronic diseases; so, the determination of nutritional status using tools reflecting various aspects has been emphasized . The MNA is a multidimensional assessment tool including information on food intake due to appetite or swallowing difficulty, anthropometric measurements including weight loss, and physical and mental functions and has been validated in patients with schizophrenia .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Factors related to malnutrition in community‐dwelling patients with schizophrenia

Kim

et al. 2018

Perspect Psychiatr Care

Self Cite

View full text Add to dashboard Cite

Purpose This study aims to identify demographic, clinical, and nutritional factors related to malnutrition in community‐dwelling patients with schizophrenia. Design and Methods We used a descriptive cross‐sectional design. Between June and July 2016, 188 community‐dwelling patients with schizophrenia were included in this study. Findings Of the 188 participants, 4.3% were classified as malnourished, and 40.4% were at risk of malnutrition. Living status, body weight, and appetite were significant factors related to malnutrition in community‐dwelling patients with schizophrenia. Practice Implication Assessment of nutritional status should be considered along with demographic and nutritional factors in community‐dwelling patients with schizophrenia.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Methodssupporting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Factors related to malnutrition in community‐dwelling patients with schizophrenia

Kim

et al. 2018

Perspect Psychiatr Care

Self Cite

View full text Add to dashboard Cite

show abstract

“…These findings suggest that pretreatment depression may have affected blood chemistry, immunologic homeostasis, and body weight, which can be taken as evidence that pretreatment depression affected nutritional status. The close correlation between psychosocial status and nutrition has been well reported in several types of human malignancies, including head and neck cancer . Furthermore, our results support the presence of an association between psychological distress, nutritional status, and systemic blood markers in HNSCC.…”

Section: Discussionsupporting

confidence: 88%

Pretreatment depression as a prognostic indicator of survival and nutritional status in patients with head and neck cancer

Kim

Roh

Lee

et al. 2015

Cancer

View full text Add to dashboard Cite

BACKGROUND The emotional status of cancer patients is associated with disease course and treatment outcomes. In this study, the authors evaluated associations between the presence of pretreatment depression and pretreatment quality of life (QOL), nutritional status, and survival outcomes in patients with head and neck squamous cell carcinoma (HNSCC). METHODS For this prospective study, 241 patients with previously untreated HNSCC who underwent curative treatments were enrolled. Patients completed the Beck Depression Inventory (BDI)‐II, the European Organization for Research and Treatment of Cancer (EORTC) 30‐item Core QOL Questionnaire (QLQ‐C30), and the EORTC QLQ Head and Neck Cancer module (QLQ‐H&N35). EORTC QLQ scores were compared between depressive and nondepressive patients, as determined according to pretreatment BDI‐II scores ≥14 and <14, respectively. Univariate and multivariate analyses were performed to assess whether the presence of depression was associated with overall survival, disease‐free survival (DFS), or posttreatment changes in nutritional status and laboratory data. RESULTS Pretreatment depression was present in 60 patients (24.9%). In depressive and nondepressive patients, the 3‐year overall survival rates were 70.8% and 82.7%, respectively (P = .045), and the 3‐year DFS rates were 63.5% and 79.1%, respectively (P = .015). After controlling for clinical factors, the presence of depression was predictive of 3‐year DFS (P = .032). EORTC QLQ‐C30 and QLQ‐HN35 scores on all items except feeding tube, nutritional supplement, and problem with mouth opening differed between depressive and nondepressive patients (P < .05). Depressive patients had lower pretreatment serum albumin levels than nondepressive patients (P < .05). CONCLUSIONS There was a significant correlation between pretreatment depression and pretreatment QOL, nutritional status, and survival outcomes in patients with HNSCC. Cancer 2016;122:131–140. © 2015 American Cancer Society.

show abstract

“…Altogether, we identified 21 studies published between 1980 and 2017 and reporting on 31 047 cancer patients as shown in Table . These studies provided acceptably reliable data for all of the 14 cancer entities selected for analysis.…”

Section: Methods and Resultsmentioning

confidence: 99%

Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review

Anker

Holcomb

Muscaritoli

et al. 2019

J cachexia sarcopenia muscle

117

View full text Add to dashboard Cite

Background Cachexia has significant impact on the patients' quality of life and prognosis. It is frequently observed in patients with cancer, especially in advanced stages, but prevalence data for the overall population are lacking. Good quality estimates of cancer cachexia in general and for each of the major cancer types would be highly relevant for potential treatment development efforts in this field. Both the USA and European Union (EU) have implemented special clinical development rules for such rare disorders what are called ‘orphan diseases’. The cut‐off level for a disease to be considered an orphan disease in the USA is 200 000 people (0.06% of the population) and EU is 5 per 10 000 people (0.05% of the population). Methods For this systematic review, we searched at PubMed (from inception to 31 January 2018) to identify clinical studies that assessed the prevalence of cachexia in cancer patients at risk. Studies reporting the prevalence of either cancer cachexia or wasting disease in the top‐10 cancer types and 4 other selected cancer types known to be particularly commonly complicated by cachexia were included in this analysis (i.e. prostate cancer, breast cancer, colorectal cancer, melanoma, endometrial cancer, thyroid cancer, urinary bladder cancer, non‐hodgkin lymphoma, lung cancer, kidney and renal pelvis cancer, head and neck cancer, gastric cancer, liver cancer, and pancreatic cancer). We calculated the current burden of cancer cachexia, disease by disease, in the USA and in the EU and compared them to the current guidelines for the definition of orphan disease status. Results We estimate that in 2014 in the USA, a total of 527 100 patients (16.5 subjects per 10 000 people of the total population), and in 2013 in the EU, a total of 800 300 patients (15.8 subjects per 10 000 people of the total population) suffered from cancer cachexia (of any kind). In the 14 separately analysed cancer types, the prevalence of cancer cachexia in the USA ranged between 11 300 (0.4/10 000, gastric cancer) and 92 000 patients (2.9/10 000, lung cancer) and in the EU between 14 300 (0.3/10 000, melanoma of the skin) and 150 100 (3.0/10 000, colorectal cancer). Conclusions The absolute number of patients affected by cancer cachexia in each cancer group is lower than the defined thresholds for orphan diseases in the USA and EU. Cancer cachexia in each subgroup separately should be considered an orphan disease.

show abstract

Depression and appetite: predictors of malnutrition in gynecologic cancer

Cited by 41 publications

References 34 publications

Factors related to malnutrition in community‐dwelling patients with schizophrenia

Factors related to malnutrition in community‐dwelling patients with schizophrenia

Pretreatment depression as a prognostic indicator of survival and nutritional status in patients with head and neck cancer

Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review

Contact Info

Product

Resources

About